• ALK-Abelló will present positive phase II peanut allergy tablet results at ACAAI’s annual meeting in Phoenix, November 12-16, 2026.
• The ALLIANCE trial tested two doses of the once-daily sublingual immunotherapy tablet against placebo in 150 patients aged 4-65.
• Treatment improved peanut tolerance across all age groups following six months of maintenance therapy, with stronger responses at higher doses.
• The tablet was well tolerated, with few treatment-related discontinuations and no treatment-related anaphylaxis or serious adverse events.
• The investigational tablet is advancing into phase III to build on these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.